Uploaded December 2024 | Updated September 2026, 3 weeks ago

---

Nicole Pfarr, Dipl.-Biol, discusses how tumor whole exome sequencing (WES) can provide valuable insights into mechanisms that drive tumor proliferation, survival, and response to therapy. WES has the potential of finding new biomarkers for targeted-therapy such as antibody-drug conjugates (ADCs).

Nicole Pfarr, Dipl.-Biol, is the head of the Molecular Pathology Diagnostic Unit and of the Next Generation Sequencing Research Facility at the Technical University of Munich, Germany.

Learn about WGS: youtu.be/19sH2UQMLAA?si=u8M2F8ti_zVDQ70x

Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

View customer spotlight videos
youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79

View Illumina webinars
youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ

View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

LinkedIn: linkedin.com/company/illumina
X: https://x.com/illumina
Instagram: instagram.com/illuminainc
Facebook: facebook.com/illuminainc
TikTok: tiktok.com/@illuminainc

#WES #multiomics #Illumina